key: cord-1052316-ye9qadcm authors: Suri, Jasjit S.; Puvvula, Anudeep; Biswas, Mainak; Majhail, Misha; Saba, Luca; Faa, Gavino; Singh, Inder M.; Oberleitner, Ronald; Turk, Monika; Chadha, Paramjit S.; Johri, Amer M.; Sanches, J. Miguel; Khanna, Narendra N.; Viskovic, Klaudija; Mavrogeni, Sophie; Laird, John R.; Pareek, Gyan; Miner, Martin; Sobel, David W.; Balestrieri, Antonella; Sfikakis, Petros P.; Tsoulfas, George; Protogerou, Athanasios; Misra, Durga Prasanna; Agarwal, Vikas; Kitas, George D.; Ahluwalia, Puneet; Kolluri, Raghu; Teji, Jagjit; Maini, Mustafa Al; Agbakoba, Ann; Dhanjil, Surinder K.; Sockalingam, Meyypan; Saxena, Ajit; Nicolaides, Andrew; Sharma, Aditya; Rathore, Vijay; Ajuluchukwu, Janet N.A.; Fatemi, Mostafa; Alizad, Azra; Viswanathan, Vijay; Krishnan, P. K.; Naidu, Subbaram title: COVID-19 pathways for brain and heart injury in comorbidity patients: A role of medical imaging and artificial intelligence-based COVID severity classification: A review date: 2020-08-14 journal: Computers in Biology and Medicine DOI: 10.1016/j.compbiomed.2020.103960 sha: 709328c86ae29ec95fe4988c484db3ade690dfa5 doc_id: 1052316 cord_uid: ye9qadcm Abstract Artificial intelligence (AI) has penetrated the field of medicine, particularly the field of radiology. Since its emergence, the highly virulent coronavirus disease 2019 (COVID-19) has infected over 10 million people, leading to over 500,000 deaths as of July 1st, 2020. Since the outbreak began, almost 28,000 articles about COVID-19 have been published (https://pubmed.ncbi.nlm.nih.gov); however, few have explored the role of imaging and artificial intelligence in COVID-19 patients—specifically, those with comorbidities. This paper begins by presenting the four pathways that can lead to heart and brain injuries following a COVID-19 infection. Our survey also offers insights into the role that imaging can play in the treatment of comorbid patients, based on probabilities derived from COVID-19 symptom statistics. Such symptoms include myocardial injury, hypoxia, plaque rupture, arrhythmias, venous thromboembolism, coronary thrombosis, encephalitis, ischemia, inflammation, and lung injury. At its core, this study considers the role of image-based AI, which can be used to characterize the tissues of a COVID-19 patient and classify the severity of their infection. Image-based AI is more important than ever as the pandemic surges and countries worldwide grapple with limited medical resources for detection and diagnosis. In December 2019, a novel coronavirus referred to as "severe acute respiratory distress syndrome coronavirus 2" (SARS-CoV-2) [1] appeared in Wuhan, the capital of Hubei Province in PR China. The disease caused by the virus was initially named "novel coronavirus pneumonia" (NCP) by the Chinese government but was subsequently renamed "coronavirus disease 2019" (COVID-19) by the World Health Organization (WHO). On January 30 th , 2020, it was declared a public health emergency of international concern (PHEIC) [2] . It is believed that SARS-CoV-2 is primarily transmitted through saliva droplets or nasal discharge [3] . The first evidence of human-to-human transmission was found by Jasper Fuk-Woo Chan et al. in their study at The University of Hong Kong-Shenzhen Hospital [4] . Due to its contagiousness (Ro=2.7), the virus has reached epidemic levels, affecting 213 countries and causing over 10 million infections and more than 500,000 deaths as of July 1 st , 2020 [5] (shown in Figure 1 ). Recent literature suggests that patients with pre-existing diseases are likely to experience severe complications from COVID-19 [6] [7] [8] [9] [10] . In one study on admitted diabetic (48, 24.9%) and non-diabetic (145, 75 .1%) COVID-19 patients, the mortality rate (81.3% vs. 47.6%) and the rate of admission to the intensive care unit (ICU) (66.7% vs. 41.4%) were significantly higher for diabetic patients. Diabetic patients also experienced severe inflammatory responses and cardiac, hepatic, and renal coagulopathy [11] . The prevalence of heart and brain injuries was also higher in COVID-19 patients with concomitant chronic conditions like diabetes, kidney disease, dyslipidemia, hypertension, [12] [13] [14] [15] , chronic obstructive pulmonary disease (COPD), and cardiovascular diseases [16] . Recent studies have shown that SARS-CoV-2 invades the thin lining of the epithelial cells of the arteries, leading to atherosclerosis [17] [18] [19] and arterial inflammatory disease-one of the major causes of cardiovascular diseases (CVDs), which also causes heart and brain injuries [12, 20, 21] . This could be due to a reduced expression of angiotensinconverting enzyme 2 (ACE2), causing endothelial dysfunction, which, in turn, aggravates existing J o u r n a l P r e -p r o o f atherosclerosis [22, 23] . It has also been observed that comorbid patients, when subjected to imagescreening, show mild to severe pre-test probability (PTP) for COVID-19 [24] . The conventional cardiovascular risk factors (CCVRF) in these comorbid patients appear strongly correlated either to their heart imaging or to surrogate biomarkers of coronary artery disease, such as carotid artery disease. Both imaging and biomarkers could be helpful in severity predictions for COVID-19 [25] [26] [27] [28] [29] [30] . Figure 2 illustrates the associations between SARS-CoV-2 and other comorbidities, such as diabetes, as well as the comparative survival rates for COVID-19 patients with and without diabetes. advantage of these imaging modalities is the visual access they provide to the scar tissue caused by the disease. A disadvantage, however, is their inability to provide a "risk assessment." The application of artificial intelligence (AI) can enhance the information provided by these imaging modalities, resulting in a more accurate characterization of the tissue and the disease process [45] [46] [47] [48] [49] [50] [51] . In fact, the combination of AI and medical imaging has been shown to improve diagnosis and risk stratification, speed up patient evaluation, enhance disease monitoring, and accelerate early intervention [40, 48, 52-57]. Thus, this review will focus on the use of AI-based tissue characterization of images of comorbid patients affected by COVID-19. The layout of this paper is as follows: Section 2 presents the pathophysiology of the four pathways leading to brain and heart injury. Section 3 summarizes the evidence related to the use of J o u r n a l P r e -p r o o f imaging during the COVID-19 pandemic. Section 4 elaborates on the use of AI-based tissue characterization for risk assessment. Finally, the paper concludes with a critical discussion. Several studies suggest that SARS-CoV-2 uses the ACE2 receptor to gain access to cells by binding to the SPIKE protein ('S' protein) on their surface [58-60] (see Figure 2 ). ACE2 and angiotensin-converting enzyme 1 (ACE1) are homolog carboxypeptidase enzymes that have different vital functions in the reninangiotensin-aldosterone system (RAAS) pathway [61] . ACE2 is widely expressed in myocardial cells [61] , type 2 pneumocytes, enterocytes, and astrocytes (in the brain) [15, 62, 63] . Thus, it is recognized as a cause of extra-pulmonary complications. Figure 3 shows the overall picture of how SARS-CoV-2 causes brain and heart injuries via four different pathways. These include (i) the neuronal pathway, (ii) the hypoxia pathway, (iii) the RAAS pathway, and (iv) the immune pathway. We will discuss these pathways and the injuries they lead to, which may manifest as viral encephalitis, infectious toxic encephalopathy, or acute cerebrovascular disease. Meanwhile, previous experimental studies have shown that beta coronaviruses in general-such as SARS-CoV-1 and MERS-can spread into and directly infect the brain when inhaled as droplets via the nasal epithelium [66, 67] . Figure 3 depicts the olfactory nerve and the olfactory bulb [68] [69] [70] -labeled as "a" and "b," respectively-on the image of the sagittal brain in the neuronal pathway. Based on recent reports, we are aware that patients infected by SARS-CoV-2 show symptoms of dysgeusia (loss of taste) and anosmia (loss of smell) [64, [71] [72] [73] . Bohmwald et al. further validate that coronaviruses that infect through the olfactory nerve and bulb can reach the brain and cerebrovascular fluid (CSF) within seven days. Additionally, these viruses have been observed to cause inflammation and demyelination [74] . The J o u r n a l P r e -p r o o f authors demonstrated in an experimental study of mice that removing the olfactory bulb from the pathway can lead to the restriction of CoV in the central nervous system (CNS) [74] . Based on this evidence, we believe that the neuronal pathway is one possible track for SARS-CoV-2. (ii) The Hypoxia Pathway (Figure 3 , pathway II): In this pathway, decreased levels of ACE2 proliferate in the lung parenchyma cells after the coronavirus has passed through, causing exaggerated neutrophils accumulation, enhanced vascular permeability, and the formation of diffuse alveolar and interstitial exudates. This ultimately leads to pulmonary edema and acute respiratory distress syndrome (ARDS) [75] . ARDS is characterized by severe abnormalities in blood gas composition resulting from an oxygen and carbon dioxide mismatch, which leads to low blood oxygen levels [76, 77] . This ongoing hypoxia can lead to myocardial ischemia and heart injury [78, 79] (see Figure 3 , pathway II-A). Hypoxia in the brain increases anaerobic metabolism in the mitochondria of the brain cells [80] , leading to cerebral vasodilatation, edema, and impaired flow. This can result in cerebral ischemia and acute cerebrovascular diseases such as acute ischemic stroke [71, 80] (see Figure 3 , pathway II-B). (iii) The RAAS Pathway after SARS-CoV-2 ( Figure 3 , pathway III): The RAAS pathway is crucial in regulating blood pressure, as well as the balance of fluid and electrolytes. Any disturbance in this pathway can trigger the pathogenesis of cardiovascular diseases [15] . Before a SARS-CoV-2 infection triggers the RAAS, Angiotensin I (Ang I) cleaves to Angiotensin II (Ang II) via ACE1. Ang II causes vasospasm. It is also a pro-inflammatory agent with prothrombotic and proliferative effects that are detrimental to vascular tone and hemostasis [77, 80] . Thus, as a counter-regulatory mechanism, ACE2 degrades Ang II and generates Ang (1-7), which counteracts the negative impacts of Ang II [75, 78] . Both ACE2 and Ang (1-7) have cardio-cerebral vascular protective effects [61] . After the triggering of SARS-CoV-2 infection, it results are in the deregulation of RAAS causing heart and brain injury in two different pathways. The main culprit is an increase in Ang II, which is caused by the decrease in ACE2 levels ( Figure 3 , pathway III-A). First, an increase in Ang II levels stimulates the adrenal cortex of the kidney, resulting in an increased production of aldosterone. Aldosterone is a steroid hormone that causes sodium and water J o u r n a l P r e -p r o o f reabsorption to increase at the distal tubule and collecting duct of the nephron [81] . This reabsorption increases blood volume and causes an elevation in blood pressure, which results in the endothelial dysfunction that causes brain and heart injury [82] . The second effect of an increase in Ang II levels (i.e., as a consequence of decreased ACE2 levels) is endothelial dysfunction leading to intimal damage in the arterial walls [21] , which can be seen during the imaging of the arterial wall (see Figure 3 , pathway III-B). This pathway can also trigger a cytokine storm, as high levels of Ang II can cause an increase in proinflammatory cytokines (see the bridge line between the RAAS and immune pathways). (iv) The Immune Pathway ( Figure 3 , pathway IV): Several recent studies have reported SARS-Cov-2 viral pneumonia [7, 77, 83, 84] having an exaggerated inflammatory response known as a "cytokine storm." This response appears to present at advanced stages of severe COVID-19, with increased levels of inflammatory cytokines leading to multiple-organ failure [85] [86] [87] . The rise in inflammatory markersincluding IL-6, IL-7, IL-12, IL-15, IL-22, TNF-α, and CXCL-10-results in the destabilization of plaque. This, in turn, can cause plaque rupture, resulting in heart and brain injury [74, 78, 88 ]. As the previous section discussed, COVID-19 uses four pathways (i.e., neuronal, hypoxia, RAAS, and immune) to cause critical heart and brain injuries in patients with comorbidities. The prevalence of myocardial injury and brain injury caused by COVID-19 [37, 68-70, 80, 85-87, 89-91] points to a need for increased use of medical imaging to expedite assessments, differential diagnoses, and patient management [35, 36, 92] with proper safety measures [93] [94] [95] [96] [97] . The seriousness of a patient's COVID-19 symptoms helps to determine which imaging modality is appropriate: portable or non-portable, and invasive or non-invasive. B-Mode ultrasound imaging is portable and can be used for low-risk patients. Meanwhile, X-ray, magnetic resonance imaging [40] and computed tomography [41] are non-portable and can be used for medium-risk patients. Intravascular ultrasound (IVUS) [98] and ventriculography are invasive imaging modalities used in highly critical cases [42, 43, 99, 100] . Amongst all the imaging modalities, ultrasound is noteworthy because it is radiation-free, portable, quick, repeatable, inexpensive, J o u r n a l P r e -p r o o f and can be performed in isolation, thus lowering the chance of spreading the COVID-19 infection [101, 102] . There are several examples of medical imaging that have led to proper treatment and healthcare management during the pandemic, ultimately reducing the mortality rate. X-ray imaging of the chest has demonstrated irregular, patchy, hazy, reticular, and widespread ground-glass opacities, indicating the progression of COVID-19 at various stages; this information can support the healthcare team in developing the most appropriate treatment plan [103] . Chest CT scans of 21 COVID-19 patients revealed in almost 18 (86%) of the patients that the disease was affecting at least one of the five lobes of their lungs [104] . Chest MRI scans of 11 COVID-19 patients showed pulmonary tissue consolidation in six (50%), diffusion-restricted regions in six (50%), and lung damage in seven (58%) [105] . Meanwhile, heart MRI studies of 26 recovered patients showed that 14 (54%) of the patients had myocardial edema. At the same time, late gadolinium enhancement was found in 8 (31%), implying that COVID-19-related cardiac injury is longstanding and requires frequent monitoring even after recovery [106] . In a different study, MR scans of a COVID-19 patient revealed myocardial inflammation, signifying myocardial injury due to a cytokine storm related to the SARS-CoV2 infection (as discussed in Section 2, Pathway IV) [107] . Several studies have also evaluated the effects of COVID-19 on the brain. In one, MRI scans revealed hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular regions [108] (shown in Figure 4 ). In another, brain MRI scans were completed for 27 patients, 12 (44%) of which produced abnormal findings [109] . Additionally, evidence of liver injury (27%) and gall bladder abnormality (83%) was found in a joint CT and ultrasound study of the abdomen [110] . Recent MRI scans of COVID-19 patients' olfactory bulbs have revealed the cause of olfactory function loss to be the interaction between SARS-CoV2 and the ACE2 protein expressed by the olfactory epithelium, which leads to inflammatory obstruction [111] . J o u r n a l P r e -p r o o f Invasive imaging is another option for diagnosing COVID-19 patients who have critical comorbidities. In one such study, IVUS, along with stenting, was performed with precautions on a COVID-19 patient with myocardial infarction [112] (shown in Figure 5) . A detailed discussion of precautions is included in section 5. In another study, takotsubo syndrome, a form of myocardial injury triggered by COVID-19, was detected using ventriculography [113] . In various studies, the medical imaging of COVID-19 patients had been crucial to ascertaining the extent of tissue damage and critical infection, although there were no visible symptoms [39, 114] . Therefore, medical imaging is the preferred way to ascertain the extent of cardiac and brain tissue damage throughout the lifetime of COVID-19 patients. COVID-19 J o u r n a l P r e -p r o o f patients with comorbidities are especially vulnerable, and so they need to be screened through medical imaging from the first day of their diagnosis. Medical imaging can help patients with deep vein thrombosis (DVT), as they are highly susceptible to severe tissue damage from COVID-19. A study showed that COVID-19 patients suffering from DVT had a worse prognosis than patients without DVT. Patients with DVT were admitted to the ICU more frequently (18.2%), discharged less frequently (48.5%), and suffered more deaths (38.5%) than those without DVT [115] . Although medical imaging can be very useful to patients and doctors alike, the exponential pandemic curve, inadequate medical facilities [116] [117] [118] , and a limited number of radiologists make the assessment, diagnosis, and management processes challenging, tedious, and error-prone. Therefore, although medical imaging can make diagnoses faster, as stated above, it will be of limited use. Given this fact, new age techniques such as artificial intelligence (AI) [119] [120] [121] applications in medical imaging for tissue characterization can make computer-aided assessments and diagnoses faster. The main reason for this is that the AI can be scaled up to match the pandemic curve, thereby meeting the immediate demands of medical image diagnoses during the COVID-19 pandemic. AI-based tests can categorize the nature of a patient's risk in one of the categories namely no-risk, low, low-medium (LM), high-medium (HM), low-high (LH), or high-high (HH) risk depending on the patient's symptoms and their severity [120, 122] as shown in Figure 6 . The imaging modality also varies with the degree of risk as follows: no imaging for no-risk, portable imaging for low and LM risk, nonportable imaging for HM and LH, and invasive imaging for HH. A probability (PTP) is performed to accurately interpret diagnostic results to categorize the patient into one of the four groups [123] [124] [125] [126] . After that, for no-risk patients, non-imaging biomarkers can be collected for risk assessment using AIbased data protocols. For low-risk patients, portable 2D/3D imaging, such as ultrasound, is used, whereas non-portable and invasive 2D/3D imaging such as MRI/CT/X-Ray/echocardiography can be used for LM patients. For HH patients, invasive imaging techniques such as IVUS and ventriculography can be used. Based on the data provided by various 2D/3D scans, AI-based medical imaging is applied for risk assessment. Further treatment is then planned based on this imaging process. In the next section, deep learning (DL)-based medical imaging is proposed for medical imaging scans, particularly ultrasounds for COVID-19 patients. Using AI and associated technologies in healthcare can significantly slow down diagnosis times, Although some caution must be exercised regarding its full-scale deployment [127] , its overall usefulness in healthcare management during times of crisis cannot be ignored [54, 55, 128, 129] . In general, AI in healthcare refers to all artificial intelligence-based technologies that make educated decisions regarding a patient's diagnosis, monitoring, treatment, and management. The importance of AI has specifically increased many folds when imaging comes into play, mainly because of large volumetric data sizes and the extensive need to characterize and quantify the disease via lesion images [130] [131] [132] . Tissue imaging and its characterization is of prime importance since it has a direct influence on decisions related to COVID-19 severity for a patient [133] [134] [135] . The main benefit of AI methods is that the machines can be used to train (by mimicking the physician's cognitive actions), and such trained models can be used to predict the disease's severity in asymptomatic patients. Within a short period, several machine learning (ML)-based techniques used the power of AI to manage COVID-19 [136, 137] . There are two types of tissue characterization that can be carried out using AI: (i) ML-based [63, 141] , and (ii) DL-based [142] . Various ML-based technologies have been developed to classify symptomatic and asymptomatic plaque from ultrasound images. For example, an ML-based technique based on support vector machines (SVM) was developed to characterize the symptomatic and asymptomatic plaques of 346 carotid scans that indicated the presence of plaque [143, 144] . SVM classifiers work by determining the maximum margin between two data clusters. First, a texture analysis [145] is used to extract the features (i.e., standard deviation, entropy, symmetry, and run percentage) in the feature extraction phase [146] . SVM with a radial basis function (RBF) kernel was then applied to the features to characterize the plaque tissue lesions. The performance accuracy was 82.4%. The higher-order spectra [130] domain provides evidence of compelling tissue characterization features related. In other work, an SVM-based (RBF kernel) classifier [46] was developed using a combination of HOS [130, 147] , discrete wavelet transforms (DWTs) [148] , and texture features [146] taken from 146 patient scans. This classifier's accuracy was 91.7%. Polynomial kernels of order two were used to characterize tissues when adapting DWT-based features, yielding an accuracy of 83.7%. Several combinations of classifiers were applied to two different carotid plaque cohorts (Portugal and the UK) comprising 346 scans. The focus was to compare and contrast different classifiers, such as SVM [45] , the Gaussian mixture model (GMM) [149] , radial basis probabilistic neural network (RBPNN) [150] , decision tree (DT) [151] , k-nearest neighbor (KNN) [152] , naive Bayes classifier (NBC) [153] , and fuzzy classifier [154] . The main features used were trace transform [155] , fuzzy gray level co-occurrence matrix (FGLCM) [156] , and fuzzy run-length matrix (FRLM) [157] . The highest fuzzy classifier accuracy achieved for the Portugal cohort was 93.1%, while the NBC and SVM-RBF kernel performed equally (85.3%). Different methods for CVD risk stratification using the AI paradigm for plaque characterization have been published [27, 28, 158] . Recently, Jamthikar et al. [159, 160] explained the role of ML for CVD/stroke risk assessment within a big data framework by fusing image-based phenotypes and conventional risk factors for CCA and bulb segments [161] . In another study, the authors discussed the preventive cardiovascular framework for coronary artery disease management in ML [63] and the big data framework. Similarly, ML and DL algorithms have been applied to CVD risk assessments in several other areas [158, 162] . Highly accurate techniques for lumen characterization [164] , stenosis estimation [165] , and cIMT measurement [56] have been developed using the deep fully convolutional network (FCN) [163] in segmentation models. ML and DL technologies are being applied during the COVID-19 pandemic to characterize lung CT images [166] [167] [168] with varying degrees of success. Kang et al. [169] applied representation learning to J o u r n a l P r e -p r o o f characterize non-infected chest CT scans from COVID-19 patients with an accuracy of 95.5%. Wang et al. [170] used a DL-based network to differentiate COVID-19 patients' CT scans from scans of noninfected people, yielding a ROC having an AUC of 0.959. Different DL-based methodologies for tissue characterization and segmentation have been implemented to differentiate diseased (fatty liver) ultrasound images (with 100% accuracy) [171, 172] and assess liver fibrosis stages using DL radionics of shear wave elastography [173] . This method is ideal for characterizing and classifying COVID-19 patients. Several studies have appeared recently in the area of lung CT classification using AI methods. They are This system is accessible worldwide [178] . Yang et al. [179] illustrated the lung segmentation in CT images by identifying pulmonary parenchyma, followed by DenseNet-based classification. This method yielded an accuracy of 92% and an AUC of 0.98. In other work, Oh et al. [180] used X-ray CHEST images as inputs for segmentation and classification. The authors used DenseNet for segmentation. The J o u r n a l P r e -p r o o f authors then used the same network for classification, adapting patch-based strategy, and demonstrating an accuracy of 88.9%. A well-implemented DL-based platform is proposed to treat COVID-19 patients with comorbidities (see Figure 9 ). The proposed DL system is trained using offline data collected from COVID-19 patients across the globe. The data is given in the form of several ultrasound scans taken from COVID-19 patients with comorbidities following specific guidelines [93] [94] [95] [96] [97] . The ROI of the tissue is obtained from the scan using the AtheroEdge TM system, which can detect plaque automatically and segment the plaque region. Similarly, ultrasound scans are taken from online patients, and ROI is extracted using the same AtheroEdge™ system. Once the DL parameters are trained using the offline data, they are used to predict the plaque vulnerability of the online data obtained from the testing patients. The predictions are used to further assess and support the clinical viability of the DL system. In this review, we summarized several imaging studies on COVID-19 patients to explore the extent to which major organs, such as the heart [106, 107] , brain [108, 109] , lungs [104, 105] , and liver, undergo due to COVID-19 infection. All the imaging studies were done on COVID-19 patients with mild to severe symptoms who were referred to the medical team for appropriate patient management. Although there are multiple imaging modalities, ultrasound is preferred over others because of its portability, which allows patients to stay in their isolation zones. Similar portability is advised for MRI [181, 182] and CT [183] scanning to decrease the spread of infection among different isolation wards. A mass portable imaging test for admitting COVID-19 patients would allow medical practitioners to devise treatment plans quickly and help save lives. For patients with severe cases of COVID-19, IVUS [98] and, ventriculography (with proper precautions) are proposed [42, 43, 99, 100] . J o u r n a l P r e -p r o o f Because AI systems can handle millions of images at a time, they can be scaled to make mass diagnoses to match the pandemic curve. J o u r n a l P r e -p r o o f AI is categorized into two types: ML and DL [54] . Predictions made by ML models depend on feature extraction algorithms. Meanwhile, DL models can extract features directly from medical imaging, thus making them clearer. We propose that a risk assessment model using AI-based imaging should be used. Initially, based on PTP tests [123] [124] [125] [126] , patients are categorized as wither no-risk, low-risk, LM, MH, LH, or HH [120, 122] . Medical imaging is then performed according to the patient's risk level. Finally, AI is applied to medical images to assess risk. DL-based tissue characterization is also proposed for ultrasound scans and extended to other imaging modalities. The DL-based system is trained using offline data and tested using online data. This system is capable of ascertaining the degree of tissue damage caused by a COVID-19 infection. In addition to AI, telemedicine and social media can be useful for monitoring patients' health. Telemedicine can be used to track patients' health using Internet of Things devices, thereby augmenting infection containment efforts [184] . Also, through the use of big data analytics, social media can be used to track patients' health and share essential research findings [185] [186] [187] . Guidelines must be followed by medical staff to prevent infection [188] [189] [190] . Specifically, medical staff members are required to wear eye protection, a disposable water-resistant gowns, and disposable gloves. Portable imaging equipment must be used to avoid moving patients. All medical equipment that needs to be touched should be disinfected after each use (as shown in Figure 10 (a)). To prevent contact, imaging equipment can be used outside the isolation room, and images can be taken through the isolation room glass (as shown in Figure 10 (b)). A disposable sterile protection cover (as shown in Figure 10 (c)) can be used to contact devices (e.g., ultrasound probes). J o u r n a l P r e -p r o o f Figure 10 : a) Safety guidelines to be followed by medical staff before performing imaging (reproduced with permission [188] ); (b) Images being taken through glass (reproduced with permission [189] ); (c) disposable sterile sheath for covering probe. (reproduced with permission [190] ). J o u r n a l P r e -p r o o f COVID-19 leads to brain and heart injury via four pathways (i.e., neuronal, hypoxia, RAAS, and immune SARS-CoV-2 and COVID-19: The most important research questions A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 2020 Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Metabolic associated fatty liver disease increases COVID----19 disease severity in non----diabetic patients Clinical characteristics and outcomes of patients with severe covid-19 with diabetes Heart disease and stroke statistics-2020 update: a report from the American Heart Association COVID-19 and the cardiovascular system The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 Angiotensin-converting enzyme 2 and renal disease. Current opinion in nephrology and hypertension Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis Organ----protective Effect of Angiotensin----converting Enzyme 2 and its Effect on the Prognosis of COVID----19 The heart in COVID19: primary target or secondary bystander? JACC: Basic to Translational Science Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation Inflammation and atherosclerosis Atherosclerosis disease management COVID-19, ACE2, and the cardiovascular consequences Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology Radiology department preparedness for COVID-19: radiology scientific expert panel Echolucency-based phenotype in carotid atherosclerosis disease for risk stratification of diabetes patients Effect of carotid image-based phenotypes on cardiovascular risk calculator: AECRS1. 0 Nonlinear model for the carotid artery disease 10----year risk prediction by fusing conventional cardiovascular factors to carotid ultrasound image phenotypes: A Japanese diabetes cohort study SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor SARS and MERS: recent insights into emerging coronaviruses Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China Virus infections in the nervous system Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. The Journal of infectious diseases Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2 Neurological manifestations in COVID----19 caused by SARS There's a new symptom of coronavirus, doctors say: Sudden loss of smell or taste Loss of sense of smell as marker of COVID-19 infection Neurologic alterations due to respiratory virus infections Recombinant human ACE2: acing out angiotensin II in ARDS therapy Fifty years of research in ARDS. Gas exchange in acute respiratory distress syndrome. American journal of respiratory and critical care medicine Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Coronaviruses and the cardiovascular system: acute and long-term implications SARS----coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS Interaction brain-lungs StatPearls [Internet The vascular endothelium and human diseases Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission Presumed asymptomatic carrier transmission of COVID-19 COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal Clinical analysis of multiple organ dysfunction syndrome in patients suffering from SARS. Zhongguo wei zhong bing ji jiu yi xue= Chinese critical care medicine= Zhongguo weizhongbing jijiuyixue Plaque Vulnerability, Plaque Rupture, and Acute Coronary Syndromes: (Multi)-Focal Manifestation of a Systemic Disease Process Into the eye of the cytokine storm Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms COVID-19 Cardiac repercussions. Revista Brasileira de Fisiologia do Exercício First case of COVID-19 infection with fulminant myocarditis complication: case report and insights Management of patients with COVID-19 in radiology departments, and indications regarding imaging studiesrecommendations of the Polish Medical Society of Radiology Just the Facts: Recommendations on Point of Care Ultrasound Use and Machine Infection Control During the COVID-19 Pandemic To resume noninvasive imaging detection safely after peak period of COVID----19: experiences from Wuhan China Art of performing dermoscopy during the times of coronavirus disease (COVID----19): simple change in approach can save the day COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel Consensus guidelines for Interventional Cardiology services delivery during COVID-19 pandemic in Australia and New Zealand. Heart, Lung and Circulation Biomedical image segmentation: advances and trends Multi modality state-of-the-art medical image segmentation and registration methodologies Ultrasound in Times of COVID-19 Point----of----care lung ultrasound in patients with COVID----19-a narrative review Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review CT imaging features of 2019 novel coronavirus (2019-nCoV) Khoruzhaya A: MRI of the lungs in patients with COVID-19: clinical case Cardiac involvement in recovered COVID-19 patients identified by magnetic resonance imaging M: Diffuse Myocardial Inflammation Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection Abdominal imaging findings in COVID-19: preliminary observations MRI evaluation of the olfactory clefts in patients with SARS-CoV-2 infection revealed an unexpected mechanism for olfactory function loss The experience of treating patients with acute myocardial infarction under the COVID----19 epidemic. Catheterization and Cardiovascular Interventions Typical takotsubo syndrome triggered by SARS-CoV-2 infection Acute pulmonary embolism and COVID-19 pneumonia: a random association? Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation Fair allocation of scarce medical resources in the time of Covid-19 Facing Covid-19 in Italy-ethics, logistics, and therapeutics on the epidemic's front line Declines in Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic: A Multicenter Tertiary Care Experience Emerging technologies to combat COVID-19 pandemic COVID-19 on the Chest Radiograph: A Multi-Reader Evaluation of an AI System Predicting COVID-19 in China Using Hybrid AI Model. IEEE transactions on cybernetics 2020 EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic COVID-19): a systematic review of imaging findings in 919 patients Accuracy and reproducibility of low-dose submillisievert chest CT for the diagnosis of COVID-19 The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society A British Society of Thoracic Imaging statement: considerations in designing local imaging diagnostic algorithms for the COVID-19 pandemic Cautions about radiologic diagnosis of COVID-19 infection driven by artificial intelligence. The Lancet Digital Health Deep learning for healthcare: review, opportunities and challenges A guide to deep learning in healthcare Artificial intelligence in radiology Theory, Case Studies, and Applications The role of artificial intelligence in medical imaging research Ultrasonic tissue characterization for diagnosis of acute myocardial infarction in the coronary care unit. The American journal of cardiology Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia Artificial intelligence and machine learning to fight COVID-19 Artificial Intelligence (AI) applications for COVID-19 pandemic Cardiovascular/stroke risk predictive calculators: a comparison between statistical and machine learning models. Cardiovascular Diagnosis and Therapy Cardiovascular/Stroke Risk Prevention: A New Machine Learning Framework Integrating Carotid Ultrasound Image-based Phenotypes and its Harmonics with Conventional Risk Factors Symtosis: A Liver Ultrasound Tissue Characterization and Risk Stratification in Optimized Deep Learning Paradigm Bishop CM: Pattern recognition and machine learning: springer Deep learning Symptomatic vs. asymptomatic plaque classification in carotid ultrasound Support-vector networks Handbook of texture analysis Image texture analysis: methods and comparisons. Chemometrics and intelligent laboratory systems Automatic identification of epileptic EEG signals using nonlinear parameters ThyroScreen system: high resolution ultrasound thyroid image characterization into benign and malignant classes using novel combination of texture and discrete wavelet transform. Computer methods and programs in biomedicine Gaussian Mixture Models. Encyclopedia of biometrics Radial basis probabilistic neural networks: Model and application Generating production rules from decision trees Distance to nearest neighbor as a measure of spatial relationships in populations Rish I: An empirical study of the naive Bayes classifier Fuzzy Logic with Engineering Applications The trace transform and its applications Incorporation of gray-level imprecision in representation and processing of digital images Texture analysis using grey level run lengths A survey on coronary atherosclerotic plaque tissue characterization in intravascular optical coherence tomography A low-cost machine learning-based cardiovascular/stroke risk assessment system: integration of conventional factors with image phenotypes. Cardiovascular diagnosis and therapy A Special Report on Changing Trends in Preventive Stroke/Cardiovascular Risk Assessment Via B-Mode Ultrasonography Does the Carotid Bulb Offer a Better 10-Year CVD/Stroke Risk Assessment Compared to the Common Carotid Artery? A 1516 Ultrasound Scan Study Rheumatoid Arthritis: Atherosclerosis Imaging and Cardiovascular Risk Assessment Using Machine and Deep Learning-Based Tissue Characterization Fully convolutional networks for semantic segmentation Deep learning fully convolution network for lumen characterization in diabetic patients using carotid ultrasound: a tool for stroke risk Ultrasound-based carotid stenosis measurement and risk stratification in diabetic cohort: a deep learning paradigm. Cardiovascular diagnosis and therapy The role of imaging in the detection and management of COVID-19: a review A review on the use of artificial intelligence for medical imaging of the lungs of patients with coronavirus disease 2019 A clinical study of noninvasive assessment of lung lesions in patients with coronavirus disease-19 (COVID-19) by bedside ultrasound Diagnosis of coronavirus disease 2019 (covid-19) with structured latent multi-view representation learning Chuansheng Zheng: A Weakly-supervised Framework for COVID-19 Classification and Lesion Localization from Chest CT Imagenet classification with deep convolutional neural networks Rethinking the inception architecture for computer vision Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis From Community Acquired Pneumonia to COVID-19: A Deep Learning Based Method for Quantitative Analysis of COVID-19 on thick-section CT Scans Deep learning-based model for detecting 2019 novel coronavirus pneumonia on high-resolution computed tomography: a prospective study Deep learning for detecting corona virus disease 2019 (COVID-19) on high-resolution computed tomography: a pilot study Deep learning covid-19 features on cxr using limited training data sets Design and optimization of a ring-pair permanent magnet array for head imaging in a low-field portable MRI system Two----dimensional imaging in a lightweight portable MRI scanner without gradient coils. Magnetic resonance in medicine Use of portable CT in the R Adams Cowley Shock Trauma Center: experiences in the admitting area, ICU, and operating room COVID-19: an unintended force for medical revolution Twitter-based learning for continuing medical education? Characterizing the propagation of situational information in social media during COVID-19 epidemic: A case study on weibo Big Data in Multimodal Medical Imaging Coronavirus (COVID-19) outbreak: what the department of radiology should know Policies and guidelines for COVID-19 preparedness: experiences from the University of Washington Franceschi F: novel coronavirus disease-19 pnemoniae: a case report and potential applications during COVID-19 outbreak J o u r n a l P r e -p r o o f • This paper presents the four pathways that can lead to heart and brain injuries following COVID-19 infection.• This study gives several insights into the role that imaging can play in the treatment of comorbid patients, based on probabilities derived from COVID-19 symptom statistics.• This study also discusses the role of image-based AI, which can be used to characterize the tissues of a COVID-19 patient J o u r n a l P r e -p r o o f We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.We understand that the Corresponding Author is the sole contact for the Editorial process. He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from." I, Mainak Biswas on behalf of all authors of the manuscript "COVID-19 Pathways for Brain and Heart Injury in Comorbidity Patients: A role of Medical Imaging and Artificial Intelligencebased COVID severity Classification: A Review" hereby declare that the details furnished above are true and correct to the best of my knowledge and belief. In case any of the above information is found to be false or untrue or misleading or misrepresenting, I am aware that I may be held liable for it.